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SUMMARY
Objective. This article presents long-term follow-up after use of topical photodynamic 
therapy (PDT) for basal cell carcinoma. PDT is treatment option for different tumors, involving 
use of specifi c agent which is activated by visible light and results in tissue destruction. 
Materials and methods. Overall 20 patients with 29 tumors were treated at the Latvian 
Oncology Center. Two illumination techniques were used: superfi cial for smaller lesions and 
multifi ber contact for nodular tumors. Clinical outcome was evaluated at 1, 7, 44 months and 
10 years after procedure. 
Results. By 10 year follow up, there were 2 tumor recurrences and in one case there was 
tumor residual tissue after fi rst PDT treatment. Overall after ten years follow-up  complete 
response was 80% of cases. 
Conclusion. Data in this study supports hypothesis that PDT could be used for the treatment 
of  non-invasive (superfi cial and nodular) basal cell carcinoma. Results in this study correspond 
with similar long-term follow-up studies.
Key words: photodynamic therapy, 5-aminolevulinic acid, basal cell carcinoma, long-term 
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INTRODUCTION
Basal cell carcinoma (BCC) – is the most common 
nonmelanoma skin cancer, which incidence grows 
every year world-wide. There are a lot of treatment op-
tions for this tumor, ranging from Mohs micrographic 
surgery to topical therapies (1). One of treatment op-
portunities is photodynamic therapy (PDT).
PDT involves the use of a photoactive dye 
(photosensitizer, PS) that is activated by exposure 
to light of a specifi c wavelength in the presence of 
oxygen. The transfer of energy from the activated 
photosensitizer to available oxygen results in the 
formation of toxic oxygen species, such as singlet 
oxygen and free radicals. These very reactive chemi-
cal species can damage target tissue. 
This method is used in many EU countries, 
USA, Canada, Japan and Russia (2).
PS is typically administered intravenously or topi-
cally, followed by illumination using a light delivery 
system suitable for the anatomical site being treated (3).
First clinical trial in Latvia using PDT with topi-
cal photosensitizer 5-aminolevulinic acid (ALA) for 
treatment of basal cell carcinoma was performed in 
2001 (4).
ALA itself has no photosensitizing effect, but is 
a natural precursor of heme circle. This pathway ends 
with the conversion of protoporphyrin IX (PpIX), 
which has photosensitizing properties, into heme by 
ferrochelatase. Many tumor types have a lower ferro-
chelatase activity than normal tissue. Therefore, upon 
administration of ALA, the capacity of ferrochelatase 
is overwhelmed, resulting in a buildup of PpIX in 
tumor cells. The absorption spectrum for PpIX is very 
similar to that of porfi mer sodium, and it is usually 
activated by light of 630-635 nm (5). 
Aim of this study was to evaluate long-term 
clinical results after ALA based BCC treatment with 
photodynamic therapy.
MATERIAL AND METHODS
The study was approved by local ethic commit-
tee. Patients signed informed consent to procedure 
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in compliance with Helsinki declaration of 1975 (re-
vised 1983). The study was performed at the Latvian 
Oncology Center.
Overall 20 patients were selected for procedure 
(8 male, 12 female; age between 29 and 86, average 
70 years) with 29 BCC and treated in spring 2001. 
Before use of PDT 4 lesions were treated surgically. 
All tumors were examined with punch biopsy 
for cytological and histological analysis for tumor 
classifi cation. All of them were classifi ed as BCC 
with minimal thickness 2 mm. Tumor size varied 
between 5×5 to 40×42 mm2.
More than half of lesions were localized on 
back, six on a face (4 – H-zone), two on trunk and 
one on an upper-arm. 
For treatment δ-aminolevulinic acid (ALA, Me-
dac, Batch-No.: M01130 AA, diluted in 0,9% saline 
solution and mixed with water and oil emulsion was 
used. Concentration for treatment was 20% by weight. 
Light was exposed to tumor itself and 10 mm beside 
visible tumor border, where ALA was also applied (4).
As light source diode laser was used (CeramOptec 
Ceralas PDT 635) with wavelength 635 nm and 2W 
output power. Two light application methods were used:
Superfi cial, for tumors with small surface area 
(17 cases)
Multifi ber contact (MFC) light application for 
nodular tumors (12 cases). Fiber amount were 3 for 
4 tumors and 6 for 8 tumors. (Figure 1) [4).
In previous studies clinical and cosmetic out-
comes were evaluated after 1, 7, 28, 44 months. 
Clinical outcome was evaluated visually and mor-
phologically by cytological or histopathological 
examination (for nodular tumors by two indepen-
dent patologist from Latvia and Sweden). In this 
study clinical outcome was evaluated 10 years after 
treatment. Data about patient clinical condition was 
gained by follow up or by phone call to patients. 
Clinical outcome was evaluated as complete 
response (CR), partial response (PR), no response 
(NR) and tumor recurrence (TR). Complete response 
determined, when disease site is clinically without 
any evidfence of BCC; partial response – when 
tumor decreased by 50% or more by seven month 
follow up; no response – when disease decreased 
by less than 50%; tumor recurrence was observed, 
when disease is remained more than six months after 
treatment (according to WHO, 1979).
For statistical analysis Kaplan-Meier method 
with help of MedCalc® software was used.
RESULTS
One month after procedure all patients (except 
2, who did not come on recall) were examined his-
Fig. 1. Multifi ber contact illumination
Fig. 2. Kaplan-Meier method for lesions divided in two groups – 
MFC group and Superfi cial illumination group
Fig. 3. Kaplan-Meier  statistical method for all lesions
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MFC Sup 1 month 7 months 44 months 10 years
1 43 F 1 Back Surgery X CR PR Residual tissue
2 40 M 2 Back None X CR CR TR
3 65 M 3 Back None X PR CR - TR
4 69 F 4 Back None X - CR CR CR
5 70 M 5 Back None X CR Disease nonspecifi c death
6 Back None X CR
7 Back None X CR
6 70 M 8 Back None X CR CR CR CR
7 73 F 9 Back None X CR CR - CR
10 Back None X CR CR - CR
8 75 M 11 Back None X CR CR - Disease non-
specifi c death
9 59 F 12 Face None X CR CR CR CR
10 65 F 13 Trunk None X CR CR CR CR
11 76 F 14 Back Surgery X CR - CR CR
15 Back Surgery X CR - CR CR
16 Back Surgery X CR - CR CR
12 29 F 17 Back None X CR CR CR CR
13 48 F 18 Trunk None X CR CR CR CR
14 73 F 19 Face None X CR CR CR CR
15 73 F 20 Face None X CR CR CR CR
21 Face None X CR CR CR CR
22 Face None X CR CR CR CR
16 86 F 23 Face None X CR - Disease nonspecifi c death
17 82 M 24 Arm None X CR Disease nonspecifi c death
18 79 M 25 Back None X - - - Disease non-
specifi c death
19 79 F 26 Back None X CR CR CR CR
20 77 M 27 Face None X CR CR CR CR
28 Back None X PR PR CR CR
29 Back None X PR PR CR CR
MFC – multifi ber contact light application, Sup – superior light application, CR – complete response, PR – partial response, 
TR – tumor recurrence.
tologically and visually. All histological samples 
with CR are without BCC. CR was observed in 25 
of 27 tumors (93%), PR was observed in 2 tumors. 
After 7 months 16 patients were examined 
in Latvian Oncological center. 20 tumors (85%) 
showed CR, 3 tumors – PR. Punch excisions con-
verted two PR to CR (4).
Interestingly that complete response was 
achieved in all cases, treated with multifi ber light 
application PDT. 
After 44 months 12 out of 20 patients came for 
recall, three died from disease not related to this study. 
Clinical outcome was following: in 17 sites CR, in 
one TR, in 1 residual tissue after PR. During follow-
up one TR and one residual tumor was observed. 
10 years after treatment clinical data were col-
lected from 15 patients (five excluded because of 
disease nonspecific death). Clinical outcomes were 
as follows: there was one tumor recurrence, other 
14 patients denied the existence of the disease. 
Again all patients, who gone through multifiber 
contact PDT, were disease free. Overall during 10 
year follow-up, two TR and one residual tumor 
were observed. 
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Three lesions that were previously treated with 
surgery showed CR after PDT. One lesion – residual 
tumor tissue after fi rst PDT treatment.
Clinical outcome after 1, 7, 44 months and 10 
years are shown in table (Table) and graphically by 
Kaplan-Maier method (Fig 2 and 3). 
DISCUSSION
There are lacks of studies that provide long-
term clinical outcome after ALA based PDT. None 
of them report about 10 year follow-up. The main 
fi nding in our study is that ALA-based PDT provides 
good clinical results. Type of tumor should be kept in 
mind for choice of illumination technique. We have 
found following results in few similar studies. Star 
et al. (2006) reported ALA based PDT with two light 
fractions with two hour interval. At mean follow-up 
of 59 months 67 superfi cial BCC were evaluated, 
CR was achieved in 56 cases (86%) (6).
Another long-term study show results 6 years 
after ALA based PDT. In this study BCC treated with 
one or two sessions of dimethylsulfoxide (DMSO)-
supported 5-aminolaevulinic acid – PDT following 
curettage. 43 lesions were evaluated clinically and 
cosmetically 72 months after treatment. CR was 
achieved in 81% cases (43/53). More that 90% long-
term CR were cleared 3 months after two-session 
therapy. Interestingly, that more than a half of recur-
rences occurred in face H-zone (7).
Sauza et al. (2009) treated non-melanoma skin 
cancers with ALA based PDT; also Bowen’s disease 
treatment was included in this study. Different types 
of BCC were included in this study. After 60 months 
follow-up CR was achieved in 7 out of 11 cases of 
BCC: 4/6 superfi cial and 3/5 nodular (8).
Mosterd et al. (2008) compared two treatment 
modalities for nodular BCC. One was surgical exci-
sion, another ALA based PDT with two times illumi-
nation at the same day and 3 weeks after debulking. 
173 primary BCC were randomly assigned either 
to PDT either surgery. Failure rates were higher 
for PDT, 30.3% of all tumors after 3 year follow-
up (9). Rhodes at el (2007) prepared similar study, 
but methylated ALA based PDT was compared to 
surgery. After 5 year follow-up, surgery group had 
lower reccurence rate (4% versus 14%). Cosmetical 
outcome was better in PDT group (10).
ALA is modifi ed to improve penetration abili-
ties and reduce side-effects. One of these modifi ca-
tions is methyl ester of ALA (m-ALA, Metvix®) (5). 
Schleier et al. (2007) compared methylated ALA 
with non modifi ed molecule clinical effects. One 
group included 13 patients with 72 tumors, another 
11 patients with 40 tumors. After 12 months results 
were approximately same for both groups – 61% CR 
for ALA group and 57.5% for m-ALA. There are 
no studies that provide long-term comparison (11).
Our long-term results are similar to other stud-
ies. There are differences from study to study be-
tween illumination parameters, procedures amount, 
application fi eld, drug use, etc. 
In our study there are no signifi cant differences 
between 5 and 10 year follow-up results, except one 
case. Probably, a bigger group of patients is required 
to support this assumption. All tumor recurrences 
or partial response occurred in back, other sites are 
clear. 
CONCLUSION
Data in this study supports hypothesis that PDT 
could be used for the treatment of non-invasive (su-
perfi cial and nodular) basal cell carcinoma. Results 
in this study correspond with similar long-term 
follow-up studies. 
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